Jazz Pharmaceuticals plc (JAZZ)

NMS – Real Time Price. Currency in USD

230.18

+2.34 (1.03%)

Market open: May 13, 2026, 9:50 AM EDT

12.05.2026

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: 2026 RBC Global Healthcare Conference on Tuesday, May 19, 2026 at 8:00 a.m. ET TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026 at 2:00 p.m.

12.05.2026

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

11.05.2026

International Markets and Jazz (JAZZ): A Deep Dive for Investors

Examine the evolution of Jazz's (JAZZ) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

08.05.2026

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

06.05.2026

Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It

Jazz Pharmaceuticals remains a Strong Buy, with Q1 2026 results affirming robust growth and a successful pivot into oncology. JAZZ's oncology segment, led by Ziihera, Modeyso, and Zepzelca, is driving double-digit sales growth and diversifying away from legacy neuroscience revenues. Ziihera's Priority Review for HER2+ GEA and multiple late-stage trials position JAZZ for significant market expansion and $2B+ peak sales potential via a HER2+ 'pipeline-in-a-product.'

06.05.2026

JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations

Jazz Pharmaceuticals tops Q1 estimates as revenues jump 19%, driven by strong Xywav, Epidiolex and oncology drug sales growth.

06.05.2026

Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

05.05.2026

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav® revenues grew 18% YoY with 425 net patient adds – – Epidiolex® revenues grew 15% YoY– – Company reaffirms 2026 revenue and expense guidance – DUBLIN, May 5, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2026 (1Q26). "Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.

27.04.2026

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the supplemental Biologics License Application (sBLA) for Ziihera® (zanidatamab-hrii) containing combinations for the first-line treatment of adult patients with HER2-positive (HER2+) unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or gastroesophageal adenocarcinoma (GEA). The FDA has set a PDUFA target action date of August 25, 2026.

01.04.2026

Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference

DUBLIN, April 1, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 15, 2026, at 8:45 a.m.

24.03.2026

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

Joint initiative aims to provide scientific validation for patient empowerment, clinician education on lower sodium intake and cardiovascular comorbidity awareness CHICAGO, March 24, 2026 /PRNewswire/ -- The American Nutrition Association (ANA) today announced its initiative with Jazz Pharmaceuticals to provide evidence-based nutritional education to support people living with narcolepsy or idiopathic hypersomnia (IH) sleep disorders associated with elevated cardiovascular (CV) and cardiometabolic (CM) risk, which make targeted, proactive nutrition even more critical. Together, they aim to translate the latest nutrition science into actionable, patient-centered guidance for people living with these conditions, and empower them to feel confident, informed, and supported in their nutritional and health choices.

Jazz Pharmaceuticals plc (JAZZ)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock

International Markets and Jazz (JAZZ): A Deep Dive for Investors

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It

JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations

Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock

International Markets and Jazz (JAZZ): A Deep Dive for Investors

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It

JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations

Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

Search stocks

Jazz Pharmaceuticals plc (JAZZ)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock

International Markets and Jazz (JAZZ): A Deep Dive for Investors

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It

JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations

Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock

International Markets and Jazz (JAZZ): A Deep Dive for Investors

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It

JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations

Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education